Sirolimus (Rapamycin): mTOR Inhibitor Immunosuppressant
Sirolimus, also known as rapamycin, is a macrolide compound produced by Streptomyces hygroscopicus. It inhibits the mammalian target of rapamycin (mTOR), a serine/threonine kinase central to cell growth and proliferation. Unlike calcineurin inhibitors, sirolimus blocks T-cell activation at a later stage by preventing the response to interleukin-2 (IL-2) signaling.
Product Profile
| CAS Number | 53123-88-9 |
|---|---|
| Molecular Formula | C51H79NO13 |
| Appearance | White to off-white powder |
| Therapeutic Category | Immunosuppressant / mTOR Inhibitor |
| Storage | Store at 2–8°C, protect from light |
Applications
Sirolimus is primarily indicated for the prophylaxis of organ rejection in renal transplant recipients, used in combination with other immunosuppressants such as corticosteroids and cyclosporine. It is formulated as oral tablets and oral solution. Beyond transplantation, sirolimus-eluting coronary stents have been widely adopted in interventional cardiology to prevent restenosis. The compound is also approved for the treatment of lymphangioleiomyomatosis (LAM), a rare lung disease. Its antiproliferative properties have generated interest in oncology applications.
Why Source from TCS
TCS supplies sirolimus to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Sirolimus (Rapamycin) 53123-88-9?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Sirolimus (Rapamycin) 53123-88-9 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Sirolimus (Rapamycin) 53123-88-9?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.